Adenosine Inhibits TNF α -Induced MMP-3 Production in MH7A RA Synoviocytes via A_{2A} Receptor Signaling

Hiroe Konishi

Hyogo College of Medicine

Shun-En Kanou

Hyogo College of Medicine Hospital

Rika Yukimatsu

Hyogo College of Medicine Hospital

Mizuki Inui

Hyogo College of Medicine Hospital

Motoya Sato

Hyogo College of Medicine Hospital

Naruto Yamamoto

Hyogo College of Medicine Hospital

Masayoshi Nakano

Hyogo College of Medicine

Masahiro Koshiba (✉ mkoshiba@hyo-med.ac.jp)

Hyogo College of Medicine

Research Article

Keywords: Adenosine, synoviocyte adenosine receptors (AdoRs), MMP-3, tumor necrosis factor-alpha (TNF α), antirheumatic effects.

Posted Date: October 15th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-829322/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Adenosine is the effector molecule; however, the contributions of synoviocyte adenosine receptors (AdoRs) are unknown, and matrix metalloproteinase 3 (MMP-3) is released by fibroblast-like synoviocytes in response to inflammatory signaling. To elucidate the therapeutic mechanisms of methotrexate, we investigated the effects of A2A AdoR activation and inhibition on tumor necrosis factor-alpha (TNF α)-induced MMP-3 release by MH7A human rheumatoid synovial cells. MH7A cells constitutively expressed membrane-associated A2A AdoRs, and HENECA enhanced intracellular cAMP. Stimulation with TNF α markedly enhanced release of MMP-3 from MH7A cells, whereas HENECA partially and dose-dependently inhibited TNF α -evoked MMP-3 release. Similarly, dbcAMP partially inhibited TNF α -induced MMP-3 release. Pretreatment with ZM241385 reversed the inhibitory effects of HENECA. Further, TNF α induced p38 MAPK and ATF-2 phosphorylation, whereas HENECA suppressed p38 MAPK and ATF-2 phosphorylation. We concluded that adenosine signaling via A2A AdoRs, adenylyl cyclase, and cAMP reduces TNF α -induced MMP-3 production by interfering with p38 MAPK/ATF-2 activity. Activation of A2A AdoR pathway and suppression of MMP-3 release may explain the antirheumatic effects of methotrexate.

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by joint pain, stiffness, and immobility, typically starting in smaller peripheral joints and eventually afflicting the larger joints [1]. While the underlying etiology is still unclear, these symptoms are associated with inflammatory proliferation of synovial cells induced by cytokines released from infiltrating lymphocytes and macrophages, eventually resulting in pannus formation and joint destruction [2, 3].

Matrix metalloproteinases (MMPs) are a family of enzymes that catalyze the degradation of extracellular matrix. Most MMPs are secreted as inactive preproteins that are activated when cleaved by extracellular proteinase [4]. The human enzyme MMP-3, also known as stromelysin-1, is expressed and secreted by fibroblast-like synoviocytes (FLSs) and chondrocytes within joints upon stimulation by inflammatory cytokines such as TNF α [5]. Once released and activated, MMP-3 degrades a wide variety of extracellular matrix proteins, including collagen types II, III, IV, IX, and X, proteoglycan, fibronectin, laminin, and elastin [6]. Moreover, MMP-3 can activate several other MMPs, including MMP-1, MMP-7, and MMP-9, thereby amplifying matrix proteolysis [7]. It is thought that these proteases contribute to joint destruction in RA by degrading cartilage extracellular matrix [8, 9]. Indeed, joint MMP-3 concentration is markedly elevated in RA compared to other MMPs [8, 10]. Further, increased production by FLS cells is frequently associated with a parallel increase in serum MMP-3 concentration. Elevated serum MMP-3 is observed in 80%–90% of RA patients, and reflects the degree of synoviocyte proliferation. Thus, serum MMP-3 may be a prognostic indicator of disease progression, especially in the early phase of RA [11]. When serum MMP-3 concentrations are high, joint destruction is expected to progress rapidly. Conversely, MMP-3 levels decrease when the condition stabilizes in response to antirheumatic drugs, including biologics [12].

Methotrexate (MTX) is recommended as a first-line drug for the initial treatment of RA [13, 14]. The antirheumatic effects of MTX are thought to be mediated by both inhibition of dihydrofolate reductase [15, 16] and by increasing the release of adenosine [17–20]. Dihydrofolate reductase is an enzyme that produces tetrahydrofolate required for nucleic acid synthesis, resulting in the suppression of immunocyte proliferation and enhanced apoptosis [17, 18]. Adenosine is a purine metabolite produced by most cells and required for adenosine triphosphate (ATP) synthesis. Further, adenosine acts as an intercellular signaling factor by stimulating four G protein-coupled adenosine receptors (A_1 , A_{2A} , A_{2B} , and A_3), all of which are expressed on synoviocytes [21, 22]. Among these, A_{2A} AdoR signaling via the G protein Gs has been shown to stimulate cAMP formation via adenylyl cyclase activation, which antagonizes T cell receptor signaling [23, 24]. In addition, intracellular cAMP may modulate MMP-3 expression [25]. RA patients treated with MTX exhibited reduced blood MMP-3 levels [26], suggesting that adenosine negatively regulates MMP-3 production by FLSs. However, the specific functions of AdoRs expressed on synovial cells have not been clarified. We therefore investigated how adenosine A_{2A} AdoR signaling affects TNF α -induced MMP-3 production in an RA FLS cell line (MH7A).

Results

Detection of functional A_{2A} AdoR expression in MH7A cells

Combined RT-PCR and western blotting revealed the expression of all four adenosine receptor mRNAs and proteins by MH7A cells. Further, expression of both A_{2A} AdoR mRNA in cytoplasm and A_{2A} AdoR protein in the membrane fraction were increased in a concentration-dependent manner by TNF α stimulation (Figure 1). The A_{2A} AdoR agonist HENECA also induced a concentration-dependent increase in intracellular cAMP (Figure 2), indicating that these membrane receptors were functionally coupled to adenylyl cyclase (AC) via Gs.

Stimulation of A_{2A} AdoRs reduced basal and TNF α -induced MMP-3 expression and release from MH7A cells

In accord with previous studies [27, 28], MH7A cells constitutively expressed MMP-3 mRNA, and expression was reduced dose-dependently by HENECA (Figure 3). In addition, MMP-3 protein release into the extracellular medium was accelerated by TNF α stimulation (Figure 4, white bars). This response was partially inhibited in a concentration-dependent manner by co-treatment with HENECA ($p < 0.05$ at 10 or 50 nM HENECA and $p < 0.01$ at 100 nM HENECA vs. TNF α alone), consistent with HENECA-induced suppression of MMP-3 mRNA expression (Figure 3). Pretreatment of MH7A cells with the A_{2A} AdoR antagonist ZM241385 blocked the inhibitory effects of HENECA on TNF α -induced MMP-3 release (Figure 4, black bars). Consistent with a contribution of A_{2A} AdoR/Gs/AC signaling to these responses, the cAMP analog dbcAMP also blocked TNF α -induced augmentation of MMP-3 production ($p < 0.01$ at 50 or 100 mM dbcAMP vs. TNF α alone) (Figure 5). Collectively, these results indicate that adenosine signaling via

the A_{2A} AdoR/Gs/AC/cAMP pathway can block TNFa-mediated MMP-3 production in MH7A synoviocytes.

Stimulation of A_{2A} AdoRs reverses TNFa-mediated activation of p38 MAPK signaling in MH7A cells

Stimulation of MH7A cells with TNFa for 10 min and 1 h significantly enhanced phosphorylation of p38 MAPK and ATF-2 compared to untreated negative control cells (Figure 6 a and b). Enhanced phosphorylation of both proteins by TNFa was inhibited by co-application of HENECA (although p-p38 remained above the basal level). These findings suggest that activation of A_{2A} AdoR/Gs/AC/cAMP signaling by HENECA may reduce TNFa-mediated MMP-3 release by partially suppressing p38 MAPK and ATF-2 activation.

Discussion

In clinical practice, serum MMP-3 levels often remain positive despite successful MTX treatment of RA, whereas serum C-reactive protein (CRP) levels fall within the reference range when MTX treatment is successful. In the present study, we provide evidence that MMP-3 remains positive following successful MTX treatment due to incomplete (although substantial) suppression of TNFa-induced production by synovial cells via A_{2A} AdoR signaling.

We first confirmed that MH7A rheumatoid synoviocytes expressed all four AdoR mRNAs expressed by primary RA FLSs [11] and that A_{2A} AdoR mRNA and cell-surface protein expression were markedly enhanced by TNFa, also in accordance with a previous report on primary RA FLSs [29]. Primary RA FLSs, however, may act differently in vitro due to differences in patient treatment history [30], so the RA FLS line MH7A was chosen for this study.

This study focused on A_{2A} AdoR for several reasons. First, expression of A_{2A} AdoR mRNA was dramatically enhanced by 1000 pg/ml TNFa, while expression levels of other AdoR mRNAs were not altered (Figure 1a). Furthermore, A_{2A} AdoR is coupled to AC via Gs and thus activation results in intracellular cAMP accumulation and ensuing PKA signaling (Figure 3), which is reported to suppress MMP-3 production in human chondrocytes [25]. Alternatively, A₁ and A₃ AdoRs are coupled to AC via Gi, leading to reduced cAMP. The selective A_{2A} AdoR agonist HENECA partially suppressed TNFa-stimulated MMP-3 production (Figure 4), a response mimicked by the cell-permeable cAMP analog dbcAMP (Figure 5). This apparent inhibitory effect was not due to HENECA, DMSO, or dbcAMP cytotoxicity, as none of these agents reduced viable cell number (data not shown). Moreover, the inhibitory effect of HENECA was significantly blocked by the selective A_{2A} AdoR antagonist ZM241385 (Figure 5), confirming that A_{2A} AdoR is the primary mediator of reduced TNFa-stimulated MMP-3 production.

We then provide evidence that this suppressive effect of A_{2A} AdoR activation stems from partial inhibition of p38 MAPK/ATF-1 signaling. Inflammatory cytokines including TNFa are known to induce rapid activation of the MAPK signaling pathway, and several studies have reported that inhibition of MAPK

phosphorylation suppresses MMP-3 production [31, 32]. Further, p38 MAPK signaling is reportedly also involved in MMP-3 production by MH7A cells [33]. Expression levels of the AP-1 family transcription factor ATF-2 were higher in FLSs from RA patients than non-patients [34] and phosphorylation of p38 and ATF-2 drives the production of MMP-3 [35, 36]. HENECA partially inhibited TNF α -induced p38 and ATF-2 phosphorylation (Figure 6), in accordance with HENECA-mediated partial inhibition of MMP-3 production by TNF α .

In RA, blood cell components such as macrophages and lymphocytes infiltrate joints and induce persistent synovitis through secretion of inflammatory cytokines, which leads to the production of MMP-3 [23, 37]. In contrast, Gs-coupled A_{2A} AdoRs increase intracellular cAMP and suppress inflammation [38, 39]. However, activation of A_{2A} AdoR signaling alone using HENECA did not reduce TNF α -induced MMP-3 production to basal levels, which may explain why MTX usually decreases but does not eliminate serum MMP-3 [40]. Shiozawa et al. reported that 87.0% of RA patients treated with MTX for 3 years still exhibited blood MMP-3 levels above 103.7 mg/ml as well as ongoing joint destruction (defined as a change in van der Heijdi modified total Sharp score ≥ 3.0) [26]. They also revealed that 94.3% of patients treated with MTX and still exhibiting rapid radiographic progression (defined as a change in van der Heijdi modified total Sharp score ≥ 5.0) had blood MMP-3 concentrations above 103.7 mg/ml [26]. Similarly, Ma et al. reported that patients with continuously elevated serum MMP-3 levels for 3–6 months had showed radiographic progression even when the therapeutic target, including CRP levels, was achieved [41]. Their prospective cohort study also showed that the serum MMP-3 level was significantly higher in progressive patients than in nonprogressive patients for an entire year and that elevated serum MMP-3 levels at baseline and the first, third, and sixth months were significant predictors of 1-year radiographic progression with cutoff points of 159 ng/ml, 264 ng/ml, 178 ng/ml, and 161 ng/ml, respectively [41]. Furthermore, matrix metalloproteinase inhibitors prevented the progression of joint destruction in rats with collagen-induced arthritis [42, 43]. These findings suggest that residual MMP-3 production is a crucial contributor to further joint destruction in MTX-treated RA patients.

The results presented here show for the first time the important contribution of FSL A_{2A} AdoRs signaling to the therapeutic mechanisms of MTX. These findings may also explain, at least in part, why MTX treatment alone does not normalize blood MMP-3 in most RA patients, and suggest that additional anti-TNF α treatments may be necessary to achieve long-term remission.

In conclusion, adenosine signaling via A_{2A} AdoRs, AC, and cAMP reduces (although does not completely block) TNF α -induced MMP-3 production, by interfering with p38 MAPK/ATF-2 activity. Activation of A_{2A} AdoR pathway and suppression of MMP-3 release may explain the antirheumatic effects of methotrexate.

Methods

Chemicals

The selective A_{2A} AdoR agonist 2-hexynyladenosine-5'-*N*-ethylcarboxamide (HENECA) was purchased from Abcam (Cambridge, UK) and TNFα from R&D Systems (Minneapolis, MN). The selective A_{2A} AdoR antagonist 4-(2-(7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5] triazin-5-ylamino)ethyl)phenol (ZM241385) and the membrane-permeable N⁶,2'-O-dibutyryl cAMP (dbcAMP) were purchased from Sigma Aldrich (St. Louis, MO). TNFα and dbcAMP were dissolved in de-ionized water while HENECA and ZM 241385 were dissolved in dimethyl sulfoxide (DMSO) for cellular administration.

Cell culture

MH7A cells were obtained from Riken Cell Bank (Saitama, Japan) and cultured in RPMI 1640 medium (Thermo Fisher Scientific, Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific) and 4× Antibiotic-Antimycotic liquid (Thermo Fisher Scientific) at 37°C under an atmosphere of 5% CO₂.

Cyclic AMP assay

MH7A cells were seeded at 1.0×10^6 /well on flat-bottomed 24-well microplates. After 90 min, cells were treated with HENECA (0–250 nM) for 0–60 min. Intracellular cAMP was measured using a cAMP EIA System (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's protocol.

Measurement of adenosine receptor and MMP-3 mRNA expression

MH7A cells were seeded at 4×10^5 /well on flat-bottomed 6-well microplates and cultured for 24 h. Cells were then treated for an additional 24 h with TNFα (0–1000 pg/ml) or HENECA (0–100 nM). Total RNA was extracted from MH7A cells using an RNeasy Mini kit and QIAshredder (QIAGEN, Tokyo, Japan) according to the manufacturer's instructions. Aliquots of RNA were reverse transcribed using a Transcriptor Universal cDNA Master (Roche Diagnostics K.K., Tokyo, Japan), and PCR reactions performed using TaqMan Universal PCR Master Mix (Thermo Fisher Scientific) according to the manufacturer's protocol on a LightCycler 480 instrument with LightCycler 480 Gene Scanning software version 1.5 (NIPPON Genetics, Tokyo, Japan). The primers used for real-time PCR were as follows: A1 AdoR (Hs00181231 _ m1), A_{2A} AdoR (Hs00169123 _ m1), A_{2B} AdoR (Hs00386497 _ m1), A3 AdoR (Hs01560269 _ m1), MMP-3 (Hs00968305 _ m1), and GAPDH (Hs02758991 _ g1) (Thermo Fisher Scientific). The amplification protocol consisted of 10 min at 95°C followed by 55 cycles of 15 s at 95°C, 1 min at 60°C, and 1 s at 72°C. Expression of MMP-3 mRNA was normalized to GAPDH mRNA expression.

Western blot analysis

Primary polyclonal antibodies against human adenosine receptor A_{2A} were purchased from Abcam, while antibodies against human phospho-p38 mitogen-activated protein kinase (p-p38 MAPK), human phospho-activating transcription factor 2 (p-ATF-2), and β-actin was purchased from Cell Signaling Technology (Tokyo, Japan). MH7A cells were seeded on 6-cm dishes at 1×10^6 /dish for 24 h, then treated

for an additional 24 h with TNF α (0–1000 pg/ml) (R&D Systems). Membrane- and cytoplasmic-protein fractions were extracted using the Mem-PER Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific), while total cellular protein was extracted using the M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific). The protein concentrations in each sample were measured using a BCA Protein Assay Reagent Kit (Thermo Fisher Scientific). Proteins were separated at 10–35 mg per gel lane by SDS-PAGE according to standard protocols and transferred onto PVDF-nylon membranes (Merck Millipore, Tokyo, Japan). Membranes were blocked with 5% non-fat milk in tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h at room temperature. After a brief wash, membranes were incubated overnight at 4°C with rabbit polyclonal antibodies against adenosine receptor A_{2A} (1:1000), p-p38 MAPK (1:1000), p-ATF-2 (1:500), and β -actin (1:1000). Blotted membranes were then washed 3 times with TBST and incubated in horseradish peroxidase (HRP)-conjugated donkey- α -rabbit IgG (1:2500, ECL Western Blotting Detection System, GE Healthcare) for 60 minutes at room temperature. Protein bands were captured, digitized, and quantified using ImageQuant LAS4000 mini (GE Healthcare).

Measurement of total MMP-3 secretion

MH7A cells were seeded on flat-bottomed 24-well microplates at 8×10^4 /well. After 24 h, cells were treated for an additional 24 h with TNF α (25 pg/ml) alone or in combination with dbcAMP (0–100 mM) or HENECA (0–100 nM) as indicated. Supernatant MMP-3 concentrations were measured using Panacurea MMP-3 (Sekisui Medical, Tokyo, Japan).

Statistical analysis

All experiments were repeated at least three times, and representative results are shown. Data are presented as mean $\pm$ standard deviation (SD). Treatment group means were compared using two-tailed unpaired t-tests. A $P < 0.05$ (two-tailed) was considered significant for all tests.

Declarations

Acknowledgements

The authors wish to thank Keiko Murakoso (Hyogo College of Medicine Hospital) for technical assistance and Enago (www.enago.jp) for the English language

Funding

The study was funded by the Hyogo College of Medicine.

Contributions

Hiroe Konishi and Masahiro Koshiba contributed to study design, acquisition and analysis of the data, and statistical calculations as well as manuscript preparation. Shun-En Kanou, Rika Yukimatsu, Mizuki Inui, Motoya Sato, Naruto Yamamoto, and Masayoshi Nakano contributed to study design and analysis

of data. HK conducted laboratory experiments. All authors revised and approved the manuscript for submission.

Competing interests

The authors declare no competing interests.

References

1. Scott, D. L., Wolfe, F. & Huizinga, T. W. J. Rheumatoid arthritis. *Lancet* **376**, 1094–1108 (2010). 10.1016/S0140-6736(10)60826-4
2. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. *N. Engl. J. Med.* **365**, 2205–2219 (2011). 10.1056/NEJMra1004965
3. Joseph, A. *et al.* Immunologic rheumatic disorders. *J. Allergy Clin. Immunol.* **125** Suppl 2, S204–S215 (2010). 10.1016/j.jaci.2009.10.067
4. Vignot, S. & Spano, J. P. Matrix metalloproteinases. *Target Ther. Oncol.*, 315–332 (2007).
5. Ribbens C, Martin y Porras M, Franchimont N, Kaiser M, Jaspar J, Damas P, *et al.* Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: Relationship with synovitis and steroid treatment. *Ann Rheum Dis.* 2002;61:161-6. doi.org/10.1136/ard.61.2.161
6. Wu, J. J., Lark, M. W., Chun, L. E. & Eyre, D. R. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. *J. Biol. Chem.* **266**, 5625–5628 (1991). 10.1016/S0021-9258(19)67640-4
7. Ogata, Y., Enghild, J. J. & Nagase, H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. *J. Biol. Chem.* **267**, 3581–3584 (1992). 10.1016/S0021-9258(19)50563-4
8. Okada, Y. Matrix-degrading metalloproteinases and their roles in joint destruction. *Mod. Rheumatol.* **10**, 121–128 (2000). 10.3109/s101650070018
9. Yoshihara, Y. *et al.* Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. *Ann. Rheum. Dis.* **59**, 455–461 (2000). 10.1136/ard.59.6.455
10. Cawston, T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. *Mol. Med. Today* **4**, 130–137 (1998). 10.1016/S1357-4310(97)01192-1
11. Lerner, A., Neidhöfer, S., Reuter, S. & Matthias, T. MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. *Best Pract. Res. Clin. Rheumatol.* **32**, 550–562 (2018). 10.1016/j.berh.2019.01.006
12. Kobayashi, A., *et al.* Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. *Arch. Pathol. Lab. Med.* **131**, 563–570 (2007). 10.5858/2007-131-563-SLOMMS
13. Cronstein, B. N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. *Pharmacol. Rev.* **57**, 163–172 (2005). 10.1124/pr.57.2.3

14. Pincus, T., Yazici, Y., Sokka, T., Aletaha, D. & Smolen, J. S. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. *Clin. Exp. Rheumatol.* **21** Suppl 31, S179–S185 (2003).
15. Schweitzer, B. I., Dicker, A. P. & Bertino, J. R. Dihydrofolate reductase as a therapeutic target. *FASEB J.* **4**, 2441–2452 (1990). 10.1096/fasebj.4.8.2185970
16. Friedman, B. & Cronstein, B. Methotrexate mechanism in treatment of rheumatoid arthritis. *Jt Bone Spine* **86**, 301–307. 10.1016/j.jbspin.2018.07.004
17. Van Ede, A. E., Laan, R. F. J. M., Blom, H. J., De Abreu, R. A. & van de Putte, L. B. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. *Semin. Arthritis Rheum.* **27**, 277–292 (1998). 10.1016/S0049-0172(98)80049-8
18. Van Ede, A. E., *et al.* Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* **44**, 1515–1524 (2001). 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7
19. Chan, E. S. L. & Cronstein, B. N. Methotrexate how does it really work? *Nat. Rev. Rheumatol.* **6**, 175–178 (2010). 10.1038/nrrheum.2010.5
20. Merrill, J. T., Shen, C., Schreiber, D., *et al.* Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. *Arthritis Rheum.* **40**, 1308–1315 (2007). 10.1002/art.1780400716
21. Koshiba, M. *et al.* 2-chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling. *Br. J. Pharmacol.* **135**, 1477–1486 (2002). 10.1038/sj.bjp.0704612
22. Stamp, L. K., Frampton, C., Hazlett, J., *et al.* Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. *Arthritis Res. Ther.* **14**, 1–9 (2012). 10.1186/ar3871
23. Huang, S., Apasov, S., Koshiba, M. & Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. *Blood* **90**, 1600–1610 (1997).
24. Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J. & Sitkovsky, M. V. Patterns of A(2A) extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A(2A) receptor monoclonal antibodies. *Mol. Pharmacol.* **55**, 614–624 (1999).
25. Chao, P. Z., Hsieh, M. S., Cheng, C. W., Lin, Y. F. & Chen, C. H. Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes. *J. Biomed. Sci.* **18**, 86 (2011). 10.1186/1423-0127-18-86
26. Shiozawa, K. *et al.* MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. *Arthritis Res. Ther.* **18**, 55 (2016). 10.1186/s13075-016-0948-7
27. Sun, H. B. & Yokota, H. Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli. *Bone* **28**, 303–309 (2001). 10.1016/S8756-3282(00)00454-3

28. Konttinen, Y. T., *et al.* Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. *Ann. Rheum. Dis.* **58**, 691–697 (1999). 10.1136/ard.58.11.691
29. Varani, K. *et al.* A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. *Arthritis Res. Ther.* **13**, R197 (2011). 10.1186/ar3527
30. Vincenzi, F., *et al.* A_{2A} adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. *PLOS ONE* **8**, e54195 (2013). 10.1371/journal.pone.0054195
31. Noh, E. M., *et al.* Cordycepin inhibits IL-1 β -induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. *Rheumatol. (Oxf. Engl.)* **48**, 45–48 (2009). 10.1093/rheumatology/ken417
32. Jia, Q., *et al.* Astragalin suppresses inflammatory responses and bone destruction in mice with collagen-induced arthritis and in human fibroblast-like synoviocytes. *Front. Pharmacol.* **10**, 94 (2019). 10.3389/fphar.2019.00094
33. Han, S. K., Jeon, S. J., Miyazawa, K., Yi, S. Y. & Yoo, Y. S. Enhancement of anti-inflammatory tendency by SB203580, p38 α specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. *Rheumatol. Int.* **26**, 972–978 (2006). 10.1007/s00296-006-0109-4
34. Zhang, X., *et al.* Sprouty2 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by down-regulating ATF2 expression and phosphorylation. *Inflammation* **44**, 91–103 (2021). 10.1007/s10753-020-01311-z
35. Zer, C., Sachs, G. & Shin, J. M. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor- α signaling. *Physiol. Genomics* **31**, 343–351 (2007). 10.1152/physiolgenomics.00080.2007
36. Zhao, Y. *et al.* Mesenchymal stem cells regulate inflammatory milieu within degenerative nucleus pulposus cells via p38 MAPK pathway. *Exp. Ther. Med.* **20**, 22 (2020). 10.3892/etm.2020.9150
37. Baud, V., Karin, M. & Karin, M. Signal transduction by TNF and its relatives. *Trends Cell Biol.* **11**, 372–377 (2001)
38. Koshiba, M. *et al.* Modification of cytokine milieu by A_{2A} adenosine receptor signaling-possible application for inflammatory diseases. *Nucleosides Nucleotides Nucleic Acids* **23**, 1101–1106 (2004). 10.1081/NCN-200027368
39. Milne, G. R. & Palmer, T. M. Anti-inflammatory and immunosuppressive effects of the A_{2A} adenosine receptor. *ScientificWorldJournal* **11**, 320–339 (2011). 10.1100/tsw.2011.22
40. Houseman, M., *et al.* Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. *Arthritis Res. Ther.* **14**, R30 (2012). 10.1186/ar3734
41. Ma, J. D., *et al.* Continuously elevated serum matrix metalloproteinase-3 for 3~6 months predicts one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. *Arthritis Res.*

42. Conway, J. G., *et al.* Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. *J. Exp. Med.* **182**, 449–457 (1995). 10.1084/jem.182.2.449
43. Ishikawa, T., *et al.* Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. *Br. J. Pharmacol.* **144**, 133–143 (2005). 10.1038/sj.bjp.0706054

Figures

a

b

Figure 1

Expression of all four adenosine receptor by MH7A cells. Expression of adenosine A2A receptors in MH7A cells and enhancement by TNF α . MH7A synoviocytes were incubated for 24 h with the indicated concentrations of TNF α . Adenosine receptor (AdoR) mRNA levels and A2A AdoR protein in the membrane fraction were then determined by real-time PCR (a) and Western blotting (b), respectively. Both A2A AdoR mRNA and membrane protein expression were enhanced by TNF α compared to untreated controls. β -actin was used as an internal control. Experiments were repeated three times and representative data are shown.

Figure 2

Detection of functional A2A AdoR expression in MH7A cells Adenosine A2A receptors in MH7A cells are functionally coupled to adenylyl cyclase and intracellular cAMP production. Cells were stimulated for 30 min with the indicated concentration of A2A AdoR agonist HENECA. Experiments were repeated three times, and data are presented as mean $\pm$ SD. $\ast p < 0.01$ vs. 0 μ M HENECA. Intracellular cAMP levels were measured using an enzyme immunoassay.

Figure 3

Stimulation of A2A AdoRs reduced basal and TNF α -induced MMP-3 expression from MH7A cells
Activation of A2A receptors suppressed constitutive expression of MMP-3 mRNA in MH7A cells. Cells were incubated for 24 h with the indicated concentration of HENECA, and MMP-3 mRNA levels estimated by RT-PCR. Experiments were repeated three times, and data are presented as mean $\pm$ SD. * $p < 0.05$ vs. 0 μ M HENECA.

Figure 4

Stimulation of A2A AdoRs reduced basal and TNFα-induced MMP-3 release from MH7A cells. Activation of A2A receptors suppressed TNFα-induced MMP-3 production by MH7A cells. MH7A cells were incubated for 24 h with TNFα (25 pg/ml) with or without the indicated concentrations of HENECA (white bars). In some experiments, the cells were also pretreated for 30 min with 1 μM of the selective A2A AdoR antagonist ZM241385 (black bars). MMP-3 was then measured in the culture medium. The suppressive effect of HENECA on TNFα-induced MMP-3 production was reversed by ZM241385 pretreatment. Experiments were repeated three times, and data are presented as mean ± SD. *p < 0.05 and **p < 0.01 vs. TNFα alone.

Figure 5

The cAMP analog dbcAMP blocked TNFα-induced augmentation of MMP-3 production. Activation of cAMP signaling suppressed TNFα-induced MMP-3 production. MH7A cells were incubated for 24 h in TNFα (25 pg/ml) with or without the indicated concentration of dbcAMP, and MMP-3 concentration measured in the culture medium. Experiments were repeated three times and data are presented as mean $\pm$ SD. $\star p < 0.01$ vs. TNFα alone.

Figure 6

Stimulation of A2A AdoRs reverses TNFα-mediated activation of p38 MAPK signaling in MH7A cells. Activation of A2A receptor signaling suppressed TNFα-induced activation of p38 MAPK and ATF-2. Cells were incubated for 10 min (a) or 1 h (b) in TNFα (1 ng/ml) with or without HENECA (1 μM). Expression levels of p-p38 and p-ATF-2 were estimated by western blotting and densitometry. HENECA suppressed TNFα-induced phosphorylation (activation) of p38 MAPK (a) and ATF-2 (b). β-actin served as the gel loading control. Experiments were repeated three times. The results are expressed as the mean ± SD. $p < 0.01$ vs. TNFα alone.